Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan

INTRODUCTION: Diagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (EGFR, ALK, ROS1, BRAF, programmed cell death-ligand 1 [PD-L1]) was approved in Japan. Information is lacking regarding real-world testing patterns...

Descripción completa

Detalles Bibliográficos
Autores principales: Yatabe, Yasushi, Yoshiki, Yasumasa, Matsumura, Koichi, Togo, Kanae, Kikkawa, Hironori, Iadeluca, Laura, Li, Benjamin, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474388/
https://www.ncbi.nlm.nih.gov/pubmed/34589999
http://dx.doi.org/10.1016/j.jtocrr.2020.100136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474388/
https://www.ncbi.nlm.nih.gov/pubmed/34589999
http://dx.doi.org/10.1016/j.jtocrr.2020.100136

Ejemplares similares